Protein engineering to create superior antibody therapeutics
David Szymkowski (Xencor, Inc)
David E. Szymkowski is Senior Director of Research at Xencor http://www.xencor.com/ Xencor is a biotechnology company that applies advanced protein engineering tools to develop better antibody drugs that are more potent, safer, and longer lasting for patients with autoimmune diseases, asthma, and cancer. Dr. Szymkowski received his B.A. at Johns Hopkins University and his Ph.D. from Penn State, and completed postdoctoral work at the Imperial Cancer Research Fund (London). With over 20 years of pharmaceutical R&D experience at Xencor and at Roche Pharmaceuticals, Dr. Szymkowski has coauthored over forty papers and reviews, and is inventor on seven issued patents. Dr. Szymkowski has been involved in the development of several antibody drugs currently in clinical trials for rheumatoid arthritis, lupus, asthma, allergy, leukemia and lymphoma. Dr. Szymkowski is a member of the American College of Rheumatology and the American Association of Immunologists, and serves on the editorial board of Drug Discovery Today.